Deals channel feed – Endpoints News

Deals channel feed

Permira proposes to take Cambrex private in $2.4B deal, stirring up CDMO M&A

6 years ago

Under a cloud of opioid lawsuits, Mallinckrodt suspends specialty generics spinoff

6 years ago

Neoleukin's quest to shake up the IL-2 space gets a boost via reverse merger with Aquinox

6 years ago

Takeda kicks up GPCR work with Sosei Heptares, dishing out $26M to get GI drug discovery going

6 years ago

Jumping into growing queue of buyers, Vertex chief targets a slate of new and 'larger' deals ahead

6 years ago

Fresh delay for $4.3B Roche/Spark deal triggers analyst concerns about gene therapy M&A

6 years ago

Gilead chief Daniel O’Day isn’t done making headlines — with more R&D deals and lots of new hires to come

6 years ago

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

6 years ago

What is Pfizer going to buy next? Albert Bourla outlines his M&A strategy in the post-Upjohn era

6 years ago

As cancer detection companies thrive, Exact Sciences looks to consolidate by spending $2.8B to acquire peer Genomic Health

6 years ago

Pfizer to combine its off-patent drug unit with Mylan

6 years ago

Failed PhIIIs after a rejection by the FDA spur Sanofi to dump its $1.7B deal with Lexicon on diabetes drug — shares crash

6 years ago

Boston's NeuroBo to use bruised Gemphire to make Nasdaq debut

6 years ago

A 2-year-old fledgling biotech steers into PhIII and nabs a quick $565M buyout deal

6 years ago

As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ in a restructured global organization

6 years ago

Celgene restructures a big Jounce pact, zeroing in on new I/O pathway with $530M deal — and bumping ICOS

6 years ago

Roche cuts loose Tamiflu OTC rights, handing Sanofi the keys as the pharma giant doubles down on Xofluza

6 years ago

Busy Gilead crew throws struggling biotech a lifeline, with some cash upfront and hundreds of millions in biobucks for HIV deal

6 years ago

Celgene racks up third Otezla approval, heating up talks about who Bristol-Myers will sell to

6 years ago

Novartis hands off 3 preclinical programs to the antiviral R&D masters at Gilead

6 years ago

Curious case of stock price moves reveals Sumitomo Dainippon is eyeing $202M buyout of Australian stem cell player

6 years ago

On a global romp, Boehringer BD team picks up its third R&D alliance for July — this time focused on IPF with $50M upfront

6 years ago

Servier scoots out of another collaboration with MacroGenics, writing off their $40M

6 years ago

Takeda preps another drug auction as execs look to further trim its post-Shire buyout debt load — report

6 years ago

First page Previous page 100 101 102103104 105 106 Next page Last page